Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha-1 for mood disorders in CVID
NL-OMON51992Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2022
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thymosin alpha 1 in common variable immunodeficiency (CVID) and major depressive disorder (MDD), sponsored by Erasmus MC. Primary endpoint: Change in peripheral blood regulatory T-cell counts. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
common variable immunodeficiency (CVID)major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON51992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51992.